Marchex (MCHX) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
17 Nov, 2025Executive summary
Q3 2025 revenue was $11.5 million, down from $12.6 million in Q3 2024, with a net loss of $1.0 million or $(0.02) per diluted share, attributed to lower call volumes, customer contract consolidations, migration revenue dilution, and macroeconomic factors.
Adjusted EBITDA improved to $0.6 million, or $1.1 million excluding $0.5 million in reorganization costs, up from $0.3 million in Q3 2024, reflecting operating leverage from organizational realignment and lower cost structure.
Accelerated sales bookings in Q3 2025 reached the highest levels of the year, driven by new product launches and industry-specific AI solutions.
The company operates a single segment focused on conversational analytics and related AI-driven solutions, serving primarily U.S. customers.
Announced an agreement in principle to acquire Archenia (also referred to as Arcaneum), a performance-based AI customer acquisition company, for a $10 million convertible note and up to 4 million share earnout, subject to audited financials, fairness opinion, and shareholder approval.
Financial highlights
Q3 2025 revenue: $11.5 million (down from $12.6 million in Q3 2024 and $11.7 million in Q2 2025); nine-month revenue: $34.6 million (down from $36.2 million year-over-year).
Net loss for Q3 2025: $1.0 million ($(0.02) per share); net loss for nine months: $2.9 million.
Gross margin for Q3 2025: 63%; operating loss margin: -8%.
Adjusted EBITDA for Q3 2025 was $0.6 million, or $1.1 million excluding reorganization costs, up from $0.3 million in Q3 2024.
Cash and cash equivalents at September 30, 2025: $10.3 million, down from $10.5 million at the end of Q2 2025.
Outlook and guidance
Revenue and adjusted EBITDA expected to be sequentially lower in Q4 2025 due to seasonality and ongoing migration dilution.
Expects 2026 revenue growth at a 10% run rate from year-end 2025 levels, with adjusted EBITDA margins of 10% or more.
Combined company (post-Archenia/Arcaneum acquisition) could achieve $60 million annualized revenue and 15%-20% growth in 2026.
Management expects resources to be sufficient to fund operations and strategic initiatives for at least twelve months, but macroeconomic factors could influence plans.
Additional equity or debt financing may be needed to support acquisition strategy and long-term obligations.
Latest events from Marchex
- AI-driven product launches and the Archenia deal set the stage for accelerated growth in 2026.MCHX
Q4 202525 Mar 2026 - Net loss narrowed and adjusted EBITDA improved as revenue is set to grow in Q3.MCHX
Q2 20242 Feb 2026 - Q3 2024 delivered $12.6M revenue, narrowed losses, and set the stage for AI-driven growth in 2025.MCHX
Q3 202417 Jan 2026 - 2025 is set for sequential growth and margin improvement, driven by new AI products and partnerships.MCHX
Q4 202424 Dec 2025 - Annual meeting to elect directors, ratify auditor, and highlight governance and compensation practices.MCHX
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and performance-based compensation highlight strong governance.MCHX
Proxy Filing1 Dec 2025 - Annual proxy details director elections, voting proposals, and governance disclosures.MCHX
Proxy Filing1 Dec 2025 - Q1 2025 revenue $11.4M, net loss $2.0M, gross margin 63%, targeting $50M+ run rate.MCHX
Q1 202525 Nov 2025 - Q2 2025 saw revenue dip 3% but net income and operational efficiency improved.MCHX
Q2 202523 Nov 2025